Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring

American Journal of Transplantation

Volumn 9, Issue 5, 2009, Pages 1087-1098

  Knechtle, S J ^a   Pascual, J ^a   Bloom, D D ^a   Torrealba, J R ^a   Jankowska Gan, E ^a   Burlingham, W J ^a   Kwun, J ^a   Colvin, R B ^b   Seyfert Margolis, V ^c   Bourcier, K ^c   Sollinger, H W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Immune Tolerance Network   (United States)

Author keywords

Alemtuzumab; Immune monitoring; Immunosuppression; Kidney; Transplantation

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC SODIUM; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANTIBODY DETECTION; ARTICLE; ASSAY; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DONOR; DRUG USE; ENDARTERITIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIP PAIN; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOLOGICAL MONITORING; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; KINETICS; MALE; PRIORITY JOURNAL; SERUM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; B-LYMPHOCYTES; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MONITORING, IMMUNOLOGIC; SIROLIMUS; TACROLIMUS;

EID: 65249176292     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02581.x     Document Type: Article

References (36)

1. Knechtle SJ, Vargo D, Fechner J et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997 63 : 1 6.
2. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 351 : 1701 1702.
3. Ikonen TS, Gummert JF, Hayase M et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000 70 : 969 975.
4. Coenen JJ, Koenen HJ, van Rijssen E et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007 39 : 537 545.
5. Knechtle SJ, Pirsch JD, H. Fechner JJ et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3 : 722 730.
6. Barth RN, Janus CA, Lillesand CA et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006 19 : 885 892.
7. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
8. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003 3 : 708 714.
9. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 7 : 518 526.
10. Stewart CC, Stewart SJ. Multiparameter data acquisition and analysis of leukocytes by flow cytometry. Methods Cell Biol 2001 64 : 289 312.
11. Stewart CC, Stewart SJ. Cell preparation for the identification of leukocytes. Methods Cell Biol 2001 63 : 217 251.
12. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000 106 : 145 155.
13. Burlingham WJ, Jankowska-Gan E, VanBuskirk AM, Pelletier RP, Orosz G. Delayed-type hypersensitivity responses. In : Lotze MT, Thomson AW eds.) Measuring Immunity. London : Elsevier, 2004 : 407 418.
14. Rodriguez DS, Jankowska-Gan E, Haynes LD et al. Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant 2004 4 : 537 543.
15. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006 81 : 81 87.
16. Torrealba JR, Katayama M, Fechner JH Jr. et al. Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. J Immunol 2004 172 : 5753 5764.
17. Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004 78 : 919 924.
18. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465 474.
19. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007 18 : 1046 1056.
20. Li Y, Koshiba T, Yoshizawa A et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004 4 : 2118 2125.
21. Martinez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007 7 : 309 319.
22. Bloom DD, Chang Z, Fechner JH et al. CD4+ CD25 +FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008 8 : 793 802.
23. Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005 35 : 3332 3342.
24. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007 56 : 3044 3056.
25. Reichardt P, Dornbach B, Rong S et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007 110 : 1519 1529.
26. Calne R, Moffatt SD, Friend PJ et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 68 : 1613 1616.
27. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005 5 : 1347 1353.
28. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004 78 : 426 433.
29. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005 80 : 457 465.
30. Vathsala A, Ona ET, Tan SY et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005 80 : 765 774.
31. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005 200 : 505 515.
32. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005 5 : 3009 3014.
33. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005 80 : 1051 1059.
34. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 6 : 2409 2417.
35. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76 : 120 129.
36. Velosa JA, Griffin MD, Larson TS et al. Can a transplanted living donor kidney function equivalently to its native partner? Am J Transplant 2002 2 : 252 259.